Related Articles
U.S. News & World Report recently evaluated 899 hospitals to determine which ones offered the very best cancer care. The common denominator for the highest-ranking hospitals is that they all rely on Elekta’s cutting-edge cancer treatment equipment. The solutions range from our flagship Elekta Unity MR-Linac, that enables a scan-plan-treat approach for accurate dose delivery…
In 2018, there were almost 55,000 new cancer cases in Chile and almost 30,00 cancer-related deaths.1 Gynecological, prostate and breast cancers in particular are on the rise in the region. To meet this situation, ONCORAD, a medical technology importer, has collaborated with Clínica Sanatorio Alemán in Concepcion Chile, to bring advanced brachytherapy technology to Chile….
Cases of cervical cancer can be found in all parts of the world, but the incidence of the disease is much greater in LMIC’s (low and middle-income countries, e.g., India, Nepal, African nations) than in Western countries. Of GLOBOCAN’s 2018 estimate of 570,000 new cervical cancer cases, 85 percent were diagnosed in LMICs, with half…
Interstitial brachytherapy’s one-day treatment visit, improved dose coverage and lower radiation exposure to healthy liver tissues were the findings of a recent first-of-its kind study1 that compared interstitial liver brachytherapy (BT) treatments of 85 patients with virtual stereotactic body radiation therapy (SBRT) plans created for the same patients. The comparative analysis, published in Brachytherapy, examined…
Highly targeted, potent radiation doses delivered with interventional radiotherapy – a brachytherapy (BT) “boost” complementary to external beam radiation therapy (EBRT) – can lead to better local tumor control and higher survival rates for a variety of different cancers, according to Professor György Kovács, a radiation oncologist Gemelli-INTERACTS (Rome, Italy). Prof. Kovács reviewed the rationale…
In the first published study evaluating the utility and clinical value of Elekta’s VeneziaTM Advanced Gynecological Applicator, investigators at Ludwig Maximillian University of Munich (LMU Munich, Germany) – which has used Venezia since 2017 – showed that the hybrid intracavitary/interstitial (IC/IS) brachytherapy (BT) applicator provides significantly improved dose coverage, while also sparing nearby organs-at-risk in a…
International data demonstrates the superior efficacy of intracavitary/interstitial brachytherapy. The Venezia applicator is applicable for stages IB, IIA/B, IIIA/B, and IVA and designed to reach the parametrium and vaginal extensions. Potent, highly targeted intracavitary/interstitial 3D image-guided adaptive brachytherapy (IGABT) is gaining increasing acceptance clinically and among national and international societies as the quintessential modality to…
A prolific user of high dose rate (HDR) brachytherapy for gynecological indications, University Hospitals Seidman Cancer Center (Cleveland, Ohio) enhanced its brachytherapy capabilities with the acquisition and recent use of Elekta’s Venezia Advanced Gynecological Applicator for the first patients. Venezia is designed to enable clinicians to easily reach the cervix, parametrium and vaginal extensions in…
As a leading innovator of precision radiation therapy solutions, Elekta is committed to ensuring that every patient has access to the best cancer care possible.
The products and product clinical indications for use described within FOCUS may not have clearance or registration in certain countries. Please consult Elekta in your country for questions concerning a product or clinical use subject. This site may contain information provided by third party sources to Elekta that does not necessarily represent the views of Elekta. Individuals interviewed provided information based on their personal experience and were not compensated for their participation. Accordingly, third party information contained in this site is provided "as is" with no guarantees of completeness, accuracy, usefulness, or timeliness.
© 2022 Elekta | FOCUS Magazine. | Privacy Policy | Cookies
